Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab plus FLOT in First-line Gastroesophageal Junction Cancer
NCT06411171Phase 3Not yet recruiting
- Start
- Jun 2024
- Primary completion
- Sep 2025
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
01
Overview
Phase 3, randomised trial of pembrolizumab in gastroesophageal junction adenocarcinoma (2 arms). Primary endpoint: Objective Response Rate at 3 years. Planned start Jun 2024; status: not yet recruiting.
02
Drugs
03
Conditions
gastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT06411171.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06411171.